All In Biotech

Drug Trial Radar · NCT07636564

Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment

A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Apr 16, 2031

Study completion Apr 16, 2032

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous lineage (ALAL) with KMT2A-translocation. Revumenib binds to a protein called menin and keeps it from binding to another protein called KMT2A. This stops or slows the growth of leukemia cells with changes in the KMT2A gene. Blinatumomab binds to CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. In addition to blinatumomab, usual treatment also includes dexamethasone, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, calaspargase pegol, doxorubicin, thioguanine, daunorubicin, vincristine and leucovorin. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Chemotherapy drugs, such as cytarabine, mercaptopurine, calaspargase pegol, doxorubicin, thioguanine, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Leucovorin is also being studied in the treatment of cancer. It is a type of chemoprotective agent and a type of chemosensitizing agent. Adding revumenib to usual treatment with blinatumomab may be safe, tolerable and more effective than blinatumomab alone in lowering the amount of leukemia in patients with B-ALL or ALAL with the KMT2A translocation.

Conditions

  • Acute Leukemia of Ambiguous Lineage
  • B Acute Lymphoblastic Leukemia
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • T Acute Lymphoblastic Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo CSF and blood sample collection

  • BlinatumomabBiological

    Given IV

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspiration

  • Calaspargase PegolDrug

    Given IV

  • Chest RadiographyProcedure

    Undergo chest x-ray

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IV or SC

  • Daunorubicin HydrochlorideDrug

    Given IV

  • DexamethasoneDrug

    Given PO or IV

  • DoxorubicinDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • Leucovorin CalciumDrug

    Given PO or IV

  • MercaptopurineDrug

    Given PO

  • MethotrexateDrug

    Given IT or IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • RevumenibDrug

    Given PO

  • ThioguanineDrug

    Given PO

  • VincristineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (Safety run-in: Cohort A)Time frame: During cycle 1 (cycle 1 length = 28 days)
  2. Measurable residual disease (MRD) negativity rate (Cohort A)Time frame: Up to 35 days after start of therapy
  3. MRD-event-free survival (EFS) (Cohort A)Time frame: From date of randomization and up to 10 years
  4. Incidence of toxicities of interest (TOI) (Cohort B)Time frame: Up to 30 days after last dose of study treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.